Literature DB >> 24287146

Predictive power of prothrombin time and serum total bilirubin for postoperative mortality after major hepatectomy with extrahepatic bile duct resection.

Yukihiro Yokoyama1, Tomoki Ebata1, Tsuyoshi Igami1, Gen Sugawara1, Masahiko Ando2, Masato Nagino3.   

Abstract

BACKGROUND: In 2011, the International Study Group of Liver Surgery defined posthepatectomy liver failure using the prothrombin time-international normalized ratio (PT-INR) and total serum bilirubin concentration (T-Bil). Data analyzing the clinical impact of PT-INR and T-Bil on postoperative mortality, however, remain limited, especially for major hepatectomy with extrahepatic bile duct resection (HEBR).
METHODS: Prospectively collected data from 545 patients who underwent HEBR in a single institution from 2002 to 2011 were analyzed. Receiver operating characteristics (ROC) analyses of PT-INR and T-Bil on postoperative days (POD) 1, 3, and 5 were used to determine optimal cu-off values for predicting postoperative mortality.
RESULTS: Most of the treated diseases were biliary tract cancers, including perihilar cholangiocarcinoma (n = 418), gallbladder carcinoma (n = 52), and intrahepatic cholangiocarcinoma (n = 27). The mean values for PT-INR and T-Bil on POD 1, 3, and 5 were significantly greater in the patients who died owing to postoperative complications than in the patients who survived. On POD 5, the area under the ROC curve for predicting postoperative mortality and the optimal cutoff value for PT-INR were 0.876 and 1.68, respectively, whereas those of T-Bil were 0.889 and 4.0 mg/dL, respectively. A combination of PT-INR and T-Bil showed strong predictive power (ie, >40% of the patients with values beyond the cutoff value for both PT-INR and T-Bil on POD 5 died).
CONCLUSION: We recommend monitoring both PT-INR and T-Bil to predict accurately which patients are at a high risk after HEBR.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24287146     DOI: 10.1016/j.surg.2013.08.022

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

Review 1.  Defining Post Hepatectomy Liver Insufficiency: Where do We stand?

Authors:  Kelly Lafaro; Stefan Buettner; Hadia Maqsood; Doris Wagner; Fabio Bagante; Gaya Spolverato; Li Xu; Ihab Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-06-11       Impact factor: 3.452

2.  A Clear Difference Between the Outcomes After a Major Hepatectomy With and Without an Extrahepatic Bile Duct Resection.

Authors:  Takehiro Takagi; Yukihiro Yokoyama; Toshio Kokuryo; Tomoki Ebata; Masahiko Ando; Masato Nagino
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

3.  Prognostic significance of preoperative neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in patients with gallbladder carcinoma.

Authors:  Y Zhang; C Jiang; J Li; J Sun; X Qu
Journal:  Clin Transl Oncol       Date:  2015-06-16       Impact factor: 3.405

4.  Preoperative sarcopenia negatively impacts postoperative outcomes following major hepatectomy with extrahepatic bile duct resection.

Authors:  Hidehiko Otsuji; Yukihiro Yokoyama; Tomoki Ebata; Tsuyoshi Igami; Gen Sugawara; Takashi Mizuno; Masato Nagino
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

5.  Surgery-Related Muscle Loss and Its Association with Postoperative Complications After Major Hepatectomy with Extrahepatic Bile Duct Resection.

Authors:  Hidehiko Otsuji; Yukihiro Yokoyama; Tomoki Ebata; Tsuyoshi Igami; Gen Sugawara; Takashi Mizuno; Junpei Yamaguchi; Masato Nagino
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

6.  Clinical Significance of Prothrombin Time in Cholangiocarcinoma Patients with Surgeries.

Authors:  Hui-Shan Wang; Xian-Xiu Ge; Quan-Peng Li; Jun-Jie Nie; Lin Miao
Journal:  Can J Gastroenterol Hepatol       Date:  2019-07-01

7.  Surgical treatment of gallbladder cancer: An eight-year experience in a single center.

Authors:  Yasuyuki Kamada; Tomohide Hori; Hidekazu Yamamoto; Hideki Harada; Michihiro Yamamoto; Masahiro Yamada; Takefumi Yazawa; Masaki Tani; Asahi Sato; Ryotaro Tani; Ryuhei Aoyama; Yudai Sasaki; Masazumi Zaima
Journal:  World J Hepatol       Date:  2020-09-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.